London
· Delayed Price · Currency is GBP · Price in EUR BRAIN Biotech AG Statistics
Total Valuation
BRAIN Biotech AG has a market cap or net worth of GBP 60.23 million. The enterprise value is 60.52 million.
| Market Cap | 60.23M |
| Enterprise Value | 60.52M |
Important Dates
The last earnings date was Tuesday, January 14, 2025.
| Earnings Date | Jan 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 8.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.54 |
| EV / Sales | 1.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -14.16 |
Financial Position
The company has a current ratio of 1.83, with a Debt / Equity ratio of 1.89.
| Current Ratio | 1.83 |
| Quick Ratio | 1.41 |
| Debt / Equity | 1.89 |
| Debt / EBITDA | n/a |
| Debt / FCF | -5.12 |
| Interest Coverage | -4.65 |
Financial Efficiency
Return on equity (ROE) is -60.16% and return on invested capital (ROIC) is -15.30%.
| Return on Equity (ROE) | -60.16% |
| Return on Assets (ROA) | -7.06% |
| Return on Capital (ROIC) | -15.30% |
| Revenue Per Employee | 145,230 |
| Profits Per Employee | -29,117 |
| Employee Count | 318 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 2.60 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.42% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -17.42% |
| 50-Day Moving Average | 3.31 |
| 200-Day Moving Average | 4.56 |
| Relative Strength Index (RSI) | 43.38 |
| Average Volume (20 Days) | 5,143 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BRAIN Biotech AG had revenue of GBP 46.18 million and -9.26 million in losses. Loss per share was -0.42.
| Revenue | 46.18M |
| Gross Profit | 25.43M |
| Operating Income | -7.50M |
| Pretax Income | -9.14M |
| Net Income | -9.26M |
| EBITDA | -4.77M |
| EBIT | -7.50M |
| Loss Per Share | -0.42 |
Balance Sheet
The company has 22.66 million in cash and 21.88 million in debt, giving a net cash position of 773,894.
| Cash & Cash Equivalents | 22.66M |
| Total Debt | 21.88M |
| Net Cash | 773,894 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 11.56M |
| Book Value Per Share | 0.48 |
| Working Capital | 17.19M |
Cash Flow
In the last 12 months, operating cash flow was -2.98 million and capital expenditures -1.29 million, giving a free cash flow of -4.27 million.
| Operating Cash Flow | -2.98M |
| Capital Expenditures | -1.29M |
| Free Cash Flow | -4.27M |
| FCF Per Share | n/a |
Margins
Gross margin is 55.07%, with operating and profit margins of -16.24% and -20.05%.
| Gross Margin | 55.07% |
| Operating Margin | -16.24% |
| Pretax Margin | -19.80% |
| Profit Margin | -20.05% |
| EBITDA Margin | -10.32% |
| EBIT Margin | -16.24% |
| FCF Margin | n/a |
Dividends & Yields
BRAIN Biotech AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -15.37% |
| FCF Yield | -7.09% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BRAIN Biotech AG has an Altman Z-Score of -0.56. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.56 |
| Piotroski F-Score | n/a |